News
25.02.2026
AI-Based ANA HEp-2 IFA Interpretation: Clinical Validation in Routine Diagnostics
Antinuclear antibody (ANA) testing by indirect immunofluorescence assay (IFA) on HEp-2 cells remains the gold standard screening method for systemic autoimmune rheumatic diseases (SARD), including systemic lupus erythematosus, systemic sclerosis and Sjögren’s syndrome. However, manual interpretation of ANA HEp-2 IFA patterns is time-consuming, operator-dependent and subject to inter-observer variability. A recent large-scale study published in […]
More details
13.02.2026
2026-04 /Medipan & GA Generic Assays at the BDRh Congress 2026 in Berlin
April 24–25, 2026 | 21st Annual Congress of the German Rheumatologists Association (BDRh)| Estrel Berlin On April 24 and 25, 2026, the 21st Annual Congress of the German Rheumatologists Association (BDRh) will take place for the first time at Estrel Berlin. Under the motto “Sharing Knowledge – Securing the Future”, the congress brings together rheumatologists, […]
More details
02.02.2026
Anti–Factor H Autoantibodies and ELISA Testing: Optimizing Diagnosis in Atypical Hemolytic Uremic Syndrome (aHUS)
Atypical hemolytic uremic syndrome (aHUS), also known as complement-mediated thrombotic microangiopathy (CM-TMA), is a rare but life-threatening condition caused by dysregulation of the alternative complement pathway. Among the known etiologies, autoantibodies against complement factor H (anti-factor H) play a critical role, accounting for approximately 10% of cases. Accurate laboratory detection of these antibodies is essential, […]
More details
12.01.2026
Cholera and Guillain–Barré Syndrome: When Epidemics Trigger Autoimmune Neuropathy
In regions affected by recurrent cholera outbreaks, overlapping infectious diseases can obscure the diagnosis of post-infectious autoimmune conditions. We recently collaborated in the publication describing a pediatric case from Yemen that illustrates how Guillain–Barré Syndrome (GBS) can emerge during a cholera outbreak, highlighting the critical role of Campylobacter jejuni infection and anti-ganglioside antibody testing 1. […]
More details
01.01.2026
2026-02 / Medipan at the WHX Labs Dubai
February 10 – 13, 2026 | Dubai World Trade Centre | Dubai, UAE Medipan at the WHX Labs Dubai 2026 formerly Medlab Middle East Medipan is proud to announce our participation in WHX Labs Dubai 2026 (formerly Medlab Middle East), one of the leading global exhibitions for laboratory diagnostics, healthcare technologies, and life sciences innovations. […]
More details
01.01.2026
Product Catalog 2026
Discover the 2026 Product Catalog – The Latest in Autoimmune Diagnostics Medipan GmbH and GA Generic Assays GmbH proudly present the 2026 Product Catalog, showcasing our expanded portfolio of diagnostic solutions for autoimmune diseases. This edition highlights the latest innovations in immunodiagnostics and equips healthcare professionals, researchers, and laboratory partners with tools to advance diagnostics […]
More details
16.12.2025
Gut Microbiome Changes and ASCA and Anti-GP2 Antibodies in IBD: Evidence from a Large Family Cohort
Inflammatory bowel diseases (IBD), which include Crohn’s disease (CD) and ulcerative colitis (UC), are chronic disorders driven by immune dysregulation, environmental triggers, genetic predisposition, and alterations in the gut microbiota. Growing evidence highlights the role of serological biomarkers in IBD in improving disease characterization, early diagnostic refinement, and patient stratification. A new large-scale prospective investigation […]
More details
20.11.2025
Anti-GAD65 antibodies: Clinical Evidence and Practical Advantages of RIA vs CLIA tests
Understanding Anti-GAD65 Antibodies and Their Clinical Significance Anti-glutamic acid decarboxylase antibodies (anti-GAD65) are among the most important biomarkers in autoimmune diseases. They play a dual diagnostic role: These antibodies can reach concentrations 100–500 times higher in neurological disease compared with diabetes, making quantitative accuracy crucial. A recently published scientific study evaluated the clinical performance of […]
More details
13.10.2025
2025-11 / Medipan & GA Generic Assays at MEDICA 2025
November 17 – 20, 2025 | Messe Düsseldorf | Düsseldorf, Germany Medipan & GA Generic Assays at MEDICA 2025 This year, Medipan & GA Generic Assays will be participating in Hall 3 – Diagnostics Booth #3G60, where we will proudly showcase our latest products, technologies, and solutions. Visitors to our booth will have the opportunity […]
More details
06.10.2025
AI in ANA Testing: A New Era in Autoimmune Diagnostics
A German Pilot Study Using AI-Assisted Interpretation of ANA Artificial intelligence is rapidly transforming medical diagnostics—from radiology to immunology. Now, a new German pilot study reveals how AI-assisted interpretation of ANA tests could lead to faster, more consistent, and more reliable diagnosis of autoimmune diseases. With this study, the University Medical Center Regensburg and Asklepios […]
More details